All Rights reserved
Brecanavir, a protease inhibitor under investigation for HIV treatment, has been discontinued, according to its manufacturer. Glaxo Smith Kline said in a press release Monday that it will stop production of brecanavir, which was in Phase II of clinical development. Trial investigators have been notified and will move their patients to other antiretrovirals.
Senior vice president Lynn Marks of the GSK Medicine Development Center for Infectious Diseases said in the press release that the company is dedicated to continuing the fight against HIV. "Despite this disappointing outcome with brecanavir, we remain unwavering in our commitment to find new solutions to meet the challenges" of HIV and AIDS, Marks said. (The Advocate)